Canada markets closed

Fennec Pharmaceuticals Inc. (FRX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
12.82-0.95 (-6.90%)
At close: 11:27AM EDT

Fennec Pharmaceuticals Inc.

68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
United States
919 636 4530

Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Mr. Rostislav RaykovCEO & Director1.22MN/A1976
Mr. Robert C. AndradeChief Financial Officer829.28kN/A1975
Mr. Adrian J. HaighChief Operating Officer544.03kN/A1959
Mr. Mark GowlandControllerN/AN/AN/A
Mr. Lei FangPresident of Pharstat IncN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Corporate Governance

Fennec Pharmaceuticals Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.